Flagship Pioneering

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Alltrna is a biotechnology company focused on decoding tRNA biology to develop novel therapeutics. It employs artificial intelligence and machine learning tools to understand the language of tRNAs, enabling the creation of diverse programmable molecules with broad therapeutic potential.

Empress Therapeutics is an early-stage biotechnology company focused on drug development and gaining new molecular insights into health and disease. The company utilizes a proprietary bio platform that integrates evolutionary principles, human molecular and genetic data, and artificial intelligence to identify advanced starting points in endogenous drug-like molecules. This innovative approach aims to enable clinicians to address a variety of serious unmet medical needs through the development of small-molecule drug candidates.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Cellarity is a therapeutics company that employs genomic technologies, data science, and artificial intelligence to develop medicines by digitizing and analyzing cellular molecular information and behaviors. The company's platform combines single-cell technologies with machine learning to quantify how cells behave in health and disease, map the network dynamics that govern those behaviors, and design medicines that direct them. Founded in 2017 and based in Cambridge, Massachusetts, Cellarity aims to advance drug discovery by targeting cellular and molecular complexity to improve the speed and success rate of therapies.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Vesalius Therapeutics is a biotechnology company dedicated to advancing the understanding and treatment of diseases responsible for the majority of human illnesses. The company has developed a platform that connects clinical patterns with the interactions of various genes, allowing for the identification of genetic circuits that contribute to disease. By creating proprietary, patient-derived, cell-based experimental models, Vesalius Therapeutics screens and characterizes drug candidates aimed at restoring the functionality of these genetic circuits. This innovative approach empowers healthcare practitioners to identify previously unrecognized clinical patterns among patient populations, ultimately enhancing the potential for targeted and effective treatments.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Alltrna is a biotechnology company focused on decoding tRNA biology to develop novel therapeutics. It employs artificial intelligence and machine learning tools to understand the language of tRNAs, enabling the creation of diverse programmable molecules with broad therapeutic potential.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Cellarity is a therapeutics company that employs genomic technologies, data science, and artificial intelligence to develop medicines by digitizing and analyzing cellular molecular information and behaviors. The company's platform combines single-cell technologies with machine learning to quantify how cells behave in health and disease, map the network dynamics that govern those behaviors, and design medicines that direct them. Founded in 2017 and based in Cambridge, Massachusetts, Cellarity aims to advance drug discovery by targeting cellular and molecular complexity to improve the speed and success rate of therapies.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing functional cures for patients with chronic diseases. Founded in 2015, the company aims to create immune-protected, engineered human cells that restore normal physiological functions without the risk of fibrosis or immune rejection. Its lead product candidate, SIG-001, is currently in Phase I/II clinical trials for preventing bleeding episodes in patients with moderate to severe Hemophilia A. Additionally, Sigilon is advancing other candidates, including SIG-005, which targets non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells for treating type 1 diabetes. The company's innovative Shielded Living Therapeutics platform leverages advances in cell engineering and proprietary biocompatible materials to offer stable and durable therapeutic solutions for a variety of chronic conditions.

Ohana Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming reproductive health through innovative molecular techniques. Founded in 2015 and originally known as VL34, Inc., the company specializes in developing reproductive medicines aimed at enhancing sperm quality and function. Ohana Biosciences addresses infertility, mitigates inherited diseases, and aims to produce a long-lasting, reversible, and non-hormonal male contraceptive. By concentrating on sperm biology rather than egg biology, the company seeks to improve fertility rates, provide non-hormonal contraception options, and reduce pregnancy-related complications.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Cellarity is a therapeutics company that employs genomic technologies, data science, and artificial intelligence to develop medicines by digitizing and analyzing cellular molecular information and behaviors. The company's platform combines single-cell technologies with machine learning to quantify how cells behave in health and disease, map the network dynamics that govern those behaviors, and design medicines that direct them. Founded in 2017 and based in Cambridge, Massachusetts, Cellarity aims to advance drug discovery by targeting cellular and molecular complexity to improve the speed and success rate of therapies.

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Foghorn Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing innovative medicines that target genetically determined dependencies within the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, Foghorn aims to manipulate gene expression to develop therapies for cancer and other serious diseases. The company is advancing multiple drug candidates, including FHD-286, a small-molecule enzymatic inhibitor designed for treating acute myeloid leukemia and uveal melanoma, and FHD-609, a protein degrader targeting BRD9 for synovial sarcoma. Additionally, Foghorn is engaged in preclinical and discovery programs that focus on selectively targeting BRM in non-small-cell lung cancer and developing modulators for ARID1B in bladder, ovarian, and endometrial cancers. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics collaborates with Merck Sharp & Dohme Corp. to explore novel oncology therapeutics.

Inzen Therapeutics is an early-stage biotechnology company focused on developing innovative treatments for chronic diseases. The company investigates cellular turnover as a significant factor in disease progression. Utilizing a platform that integrates mass spectrometry, machine learning, and advanced genetic and chemical biological technologies, Inzen aims to create novel therapeutic products. Its research targets various health conditions, including cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. By leveraging these technologies, Inzen seeks to provide medical practitioners with effective treatment options for complex health issues.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Helicos BioSciences Corporation (Helicos) is a life sciences company, which has developed technology focused on the research, drug discovery and clinical diagnostics markets. Its True Single Molecule Sequencing (tSMS) technology enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA) (cDNA) and its approach of direct sequencing of RNA. Its Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA or RNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process and disposable supplies.

Agios Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies in the field of cellular metabolism. It discovers and develops medicines for various indications, including hematologic malignancies, solid tumors, and rare genetic diseases.

Helicos BioSciences Corporation (Helicos) is a life sciences company, which has developed technology focused on the research, drug discovery and clinical diagnostics markets. Its True Single Molecule Sequencing (tSMS) technology enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA) (cDNA) and its approach of direct sequencing of RNA. Its Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA or RNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process and disposable supplies.

Agios Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies in the field of cellular metabolism. It discovers and develops medicines for various indications, including hematologic malignancies, solid tumors, and rare genetic diseases.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

Codon Devices is a biotechnology company that develops, builds, and supplies synthetic biology products for research. It creates synthetic biological parts and offers a BioLOGIC Engineering Platform that integrates design algorithms with assay and protein engineering to design, discover, and optimize proteins for specific applications. The company also operates a BioFAB Production Platform that manufactures synthetic genes.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

Helicos BioSciences Corporation (Helicos) is a life sciences company, which has developed technology focused on the research, drug discovery and clinical diagnostics markets. Its True Single Molecule Sequencing (tSMS) technology enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA) (cDNA) and its approach of direct sequencing of RNA. Its Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA or RNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process and disposable supplies.

Codon Devices is a biotechnology company that develops, builds, and supplies synthetic biology products for research. It creates synthetic biological parts and offers a BioLOGIC Engineering Platform that integrates design algorithms with assay and protein engineering to design, discover, and optimize proteins for specific applications. The company also operates a BioFAB Production Platform that manufactures synthetic genes.

CGI Pharmaceuticals, founded in 2000 from Yale University, specializes in the discovery and development of small molecule therapeutics targeting oncology and allergy/autoimmune/inflammatory diseases. The company employs a distinctive chemical-genetics approach known as ASKA (Analog Sensitive Kinase Alleles) to investigate kinase function, collaborating with various biotech and pharmaceutical partners. CGI has developed a proprietary library of over 50,000 small molecule kinase inhibitors, all designed and synthesized in-house. Its comprehensive drug discovery infrastructure includes expertise in kinase biology, chemistry, lead generation, and drug metabolism/pharmacokinetics (DMPK). CGI has been granted eight U.S. patents for its innovative kinase inhibitors, and all of its drug discovery and development programs are derived from candidates identified within its proprietary library. Notable programs focus on Btk, a B-cell kinase for multiple indications, and Syk, which regulates the functions of mast cells, monocytes, macrophages, and B-cells.

Celexion, LLC is a bioengineering company based in Cambridge, Massachusetts, founded in 2009. The company specializes in developing platform technologies and products for various sectors, including pharmaceuticals, industrial applications, agriculture, and life sciences research. Celexion offers a range of services that include antibody discovery, scaffold creation, reformatting, affinity maturation, humanization, and metabolic pathway development. Additionally, it provides life science tools and product development services to its partners, leveraging its expertise to support advancements in these fields. As of April 2015, Celexion operates as a subsidiary of Agenus Inc.

Provides clinical samples for commercial sale and applying human genetics to target validation for drug discovery as a commercial service.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

Applied Genomic Technology Capital Funds (www.agtcfunds.com) is a new venture capital group focused on investment opportunities enabled by the genomic revolution. AGTC Funds will invest in start-up and early stage companies that apply genomic information and technologies to develop products or services that create significant shareholder value. Formed by NewcoGen Group, in conjunction with OneLiberty Ventures, AGTC Funds' limited partners include both institutional investors and corporations with a strategic interest in genomics. As the first specialty fund focused on this sector, AGTC expects to play a leadership role in selecting, funding and developing new genomics-application companies.

AnVil, Inc., a life sciences discovery company, provides in silico drug discovery and drug development solutions. The company specializes in exploring data sets in DNA microarrays, protein microarrays, cheminformatics, screening, and clinical trial data for pharmaceutical, biotechnology, genomics, and proteomics industries. It combines data mining, statistical analysis, and visualization methods to reveal information in data sets from healthcare and health insurance clients. The company also develops algorithms and tools that support the analysis of data, disease identification, and outcome measure definitions. AnVil, Inc. was formerly known as AnVil Informatics.

Quotient Therapeutics is a biotechnology company focused on developing transformative medicines through the application of somatic genomics. The company employs a unique platform that integrates four essential steps—phenotyping, isolation, genotyping, and computation—to identify and study naturally selected targets for therapeutic development. This methodology allows Quotient Therapeutics to guide drug development more effectively by utilizing insights gained from human biology, ultimately aiming to address pressing medical needs with innovative solutions.